Prior Local Treatment Does Not Impact Survival Benefit of Enzalutamide/ADT in mHSPC
May 14th 2022Results from a post-hoc analysis of ARCHES showed that the enzalutamide plus ADT significantly improved survival, as well as key secondary end points, compared with placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.
Read More
Darolutamide Continues to Show Strong Efficacy in nmCRPC After 3 Years, Regardless of Prior Therapy
May 14th 2022Findings from a post-hoc analysis of the phase 3 ARAMIS clinical trial shows positive efficacy and consistent safety and tolerability with darolutamide in patients with nonmetastatic castration resistant prostate cancer, despite type of prior local therapy.
Read More
Interim Data Targeting CD117 Show Promising MRD Results and Safety in MDS/AML
April 27th 2022JSP191 combined with fludarabine, and low-dose total body radiation demonstrated facilitation of full donor myeloid chimerism, clearing of minimal residual disease, and a well-tolerated safety profile in older patients with myelodysplastic syndrome/acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.
Read More
CAR T Cells Shown Effective Without Increased Risk of CRS or ICANS in CNS-Involved LBCL
April 25th 2022Looking at 4 CAR T-cell agents for the treatment of large B-cell lymphoma, a systematic review and analysis showed that these therapies do not appear to increase the risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome.
Read More
GVHD Prophylaxis After TBI Decreases Rates of GVHD in Hematologic Malignancies
April 25th 2022Total body irradiation (TBI) regimen and myeloablative transplantation followed by a graft-versus-host disease (GVHD) prophylaxis regimen resulted in a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies
Read More
Comparable Efficacy Profile Shown in Axi-cel and Tisa-Cel in Follicular Lymphoma
April 25th 2022Match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in the ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar outcomes in regard to efficacy between the 2 cellular therapies.
Read More
Long-Term OS Data for Axi-Cel Hint Short-Term EFS is a Surrogate End Point for R/R LBCL
April 24th 2022According to a long-term analysis of the ZUMA-1 study, the overall survival rate yielded by axicabtagene ciloleucel may support 1- and 2-year event-free survival as a surrogate end point in relapsed/refractory large B-cell lymphoma.
Read More
Epigenetic Biomarker Predicts Resistance to CAR T-Cell Therapy in ALL
April 12th 2022Molecular characteristics associated with resistance to CD19-directed chimeric antigen receptor T-cell therapy for pediatric acute lymphoblastic leukemia can hopefully improve patient selection and eligibility for therapy.
Read More
gLOH-High May Be a Marker for Improved Response to Talazoparib in mCRPC
April 12th 2022Results from a post-hoc exploratory analysis of the TALAPRO-1 study signal that high genomic loss of heterozygosity may be assiciated with enhanced response to talazoparib in patients with metastatic castration-resistant prostate cancer.
Read More
Nivolumab Plus Chemotherapy Represents New SOC for Resectable NSCLC
April 11th 2022Findings of CheckMate 816 show improved event-free survival and partial complete response and promising overall survival results with the use of neoadjuvant nivolumab in combination with chemotherapy for patients with resectable NSCLC.
Read More
Nivo/Ipi Induces Promising Response in Advanced tTMB- and bTMB-High Solid Tumors
April 11th 2022Results from the phase 2 CheckMate-848 study show that nivolumab in combination and ipilimumab may be effective for the treatment of advanced or metastatic tumor mutational burden–high solid tumors that were refractory to standard therapies.
Read More
Roughly 15% of Nonclonal Recurrent DCIS Cases May Be Undertreated, Research Suggests
April 10th 2022According to Tanjina Kader, PhD, 12% of patients in the cohort who developed new, independent primary tumors raised the question of whether using these genetic biomarkers for prediction of recurrence is a good idea.
Read More